RxDoctor Payments Data

Bao-Anh Bui, MD

Family Medicine · Fayetteville, NCNPI 1578787024

Payments from drug & device makers

$828in general payments, 2019–2025

Across 37 payments — averaging $22.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$596
  • Novo Nordisk$125
  • Abbott$51
  • Johnson & Johnson$25
  • Amarin Pharma, Inc.$18
  • Pfizer$14

What the payments were for

  • Food & beverage$828100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)29$596
Novo Nordisk1$125
Abbott3$51
Johnson & Johnson2$25
Amarin Pharma, Inc.1$18
Pfizer1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$828 in reported general payments places this provider in the 65th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$52,772
Medicare patients
107
Services billed
535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate27$41,416
TrulicityDulaglutide26$39,661
EliquisApixaban19$32,216
OzempicSemaglutide23$31,322
JardianceEmpagliflozin15$20,825
MounjaroTirzepatide12$12,053
JanumetSitagliptin Phos/Metformin Hcl11$10,199
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$6,826
SymbicortBudesonide/Formoterol Fumarate15$5,772
Atorvastatin Calcium313$3,933
Losartan Potassium172$2,210
Metoprolol Succinate116$2,208
Omeprazole102$2,053
Celecoxib56$2,002
Gabapentin89$1,926

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$32,21619 claims
Novo NordiskOzempic$125$31,32223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →